• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CymaBay Therapeutics Inc. - Common Stock (NQ:CBAY)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 32.36 (5)
Ask (Size) 32.49 (100)
Prev. Close 32.48
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 84,677,939
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 3/21
March 21, 2024
Via Investor Brand Network
News headline image
Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production ↗
March 15, 2024
Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yescarta and Tecartus, Gilead aims to diversify into oncology. Anticipating a... 
Via Benzinga

Performance

More News

Read More
News headline image
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs ↗
March 14, 2024
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Everi Holdings Inc. (NYSE – EVRI), Sterling Check Corp. (Nasdaq – STER), Societal CDMO Check Corp. (Nasdaq – SCTL)
February 29, 2024
From Brodsky & Smith LLC
Via GlobeNewswire
CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 2/21
February 21, 2024
Via Investor Brand Network
CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 2/13
February 13, 2024
Via Investor Brand Network
CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 1/25
January 25, 2024
Via Investor Brand Network
News headline image
CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAY
February 16, 2024
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Analysts see over 50% gains in these 2 mid-cap biotech stocks
February 14, 2024
Via MarketBeat
Topics Artificial Intelligence
News headline image
CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst ↗
February 13, 2024
Via Benzinga
News headline image
Fear & Greed Index Remains In 'Extreme Greed' Zone Ahead Of Inflation Data; Dow Hits Record high ↗
February 13, 2024
Via Benzinga
Topics Economy Stocks
News headline image
6 Analysts Have This to Say About CymaBay Therapeutics ↗
December 15, 2023
Via Benzinga
News headline image
Recap: CymaBay Therapeutics Q3 Earnings ↗
November 07, 2023
Via Benzinga
News headline image
Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B ↗
February 12, 2024
Via Benzinga
Topics Stocks
News headline image
Dow Up Triple Digits, Hits Fresh Highs ↗
February 12, 2024
Via Talk Markets
Topics Economy Stocks
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Masonite International Corporation (NYSE – DOOR), ZeroFox Holdings, Inc. (Nasdaq – ZFOX), RayzeBio, Inc. (Nasdaq – RYZB)
February 12, 2024
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Why is CymaBay (CBAY) Stock Up 25% Today? ↗
February 12, 2024
Via InvestorPlace
News headline image
CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday ↗
February 12, 2024
Via Benzinga
Topics Stocks
News headline image
Health Care Company Gilead Sciences Announces Acquisition of CymaBay Therapeutics ↗
February 12, 2024
Via Benzinga
News headline image
CBAY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CymaBay Therapeutics, Inc. Is Fair to Shareholders
February 12, 2024
From Halper Sadeh LLC
Via Business Wire
News headline image
Drugmaker Gilead Sciences Scoops Up Liver-Disease Focused CymaBay Therapeutics For $4.3B ↗
February 12, 2024
Via Benzinga
News headline image
CymaBay Stock Rockets After Gilead Sciences Unveils $4.3 Billion Acquisition ↗
February 12, 2024
Via Investor's Business Daily
News headline image
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
February 12, 2024
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Why CymaBay Morphed From Dollar Stock To Biotech Rocket ↗
December 28, 2023
Via Investor's Business Daily
News headline image
Raymond James Maintains Strong Buy Rating for CymaBay Therapeutics: Here's What You Need To Know ↗
November 08, 2023
Via Benzinga

Frequently Asked Questions

Is CymaBay Therapeutics Inc. - Common Stock publicly traded?
Yes, CymaBay Therapeutics Inc. - Common Stock is publicly traded.
What exchange does CymaBay Therapeutics Inc. - Common Stock trade on?
CymaBay Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for CymaBay Therapeutics Inc. - Common Stock?
The ticker symbol for CymaBay Therapeutics Inc. - Common Stock is CBAY on the Nasdaq Stock Market
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap